Evidence map›Paper›PMID 25160801›Full record

ArticleJournal of cellular physiology2015

Signaling pathways involved in megakaryocyte-mediated proliferation of osteoblast lineage cells.

Ying-Hua Cheng, Drew A Streicher, David L Waning, Brahmananda R Chitteti, Rita Gerard-O'Riley, Mark C Horowitz, Joseph P Bidwell, Fredrick M Pavalko, Edward F Srour, Lindsey D Mayo and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of cellular physiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Ying-Hua ChengDepartment of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, Indiana.
Drew A Streicher
David L Waning
Brahmananda R Chitteti
Rita Gerard-O'Riley
Mark C Horowitz
Joseph P Bidwell
Fredrick M Pavalko
Edward F Srour
Lindsey D Mayo
Melissa A Kacena
Indiana University School of MedicineYale University · US

Funding

Tumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI Jun Wan · 1999 to 2026
$59.3M
Quality Assurance and Quality Control Project Management: Improving Submissions and Study Conduct in the Human Subjects Research Prior Approval ProcessUL1TR002529 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI MOE, SHARON M, WIEHE, SARAH ELIZABETH · 2018 to 2022
$27.2M
Indiana Clinical and Translational Sciences InstituteUL1TR001108 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$23.3M
INDIANA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE (UL1): BPCAUL1RR025761 · NCRR · INDIANA UNIVERSITY INDIANAPOLIS · PI SHEKHAR, ANANTHA · 2008 to 2011
$21.0M
Project-005U54DK106846 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI Reuben Kapur, Karen Elizabeth Pollok · 2015 to 2026
$9.7M
Regulating hematopoietic stem cells and hematopoiesis for clinical efficacyP30DK090948 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI BROXMEYER, HAL E., SROUR, EDWARD F · 2010 to 2014
$3.7M
Short-Term Training Program In Biomedical SciencesT35HL110854 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI Brittney-Shea Herbert, Catherine Rufatto Sears · 2012 to 2026
$3.4M
Extrinsic Modulation of Hematopoietic Stem Cell FateR01HL055716 · NHLBI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI SROUR, EDWARD F · 1995 to 2010
$2.7M
Indiana Clinical and Translational Science Institute-K12 ProgramKL2RR025760 · NCRR · INDIANA UNIVERSITY INDIANAPOLIS · PI SHEKHAR, ANANTHA · 2008 to 2011
$2.2M
Mechanical Signaling through Osteoblast Focal AdhesionsR01AR052682 · NIAMS · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI PAVALKO, FREDRICK M · 2007 to 2011
$1.8M
Regulation of Osteoblast Function by Megakaryocytes: Key Signaling ProteinsR01AR060332 · NIAMS · INDIANA UNIVERSITY INDIANAPOLIS · PI BRUZZANITI, ANGELA, KACENA, MELISSA A · 2011 to 2015
$1.7M
Thrombopoietin: A novel regulator of bone healingR01AR060863 · NIAMS · INDIANA UNIVERSITY INDIANAPOLIS · PI KACENA, MELISSA A · 2012 to 2016
$1.7M
NCATS NIH HHS UL1 TR001108NCATS NIH HHS UL1TR001108NCI NIH HHS P30 CA082709NCI NIH HHS R01 CA109262NCRR NIH HHS KL2 RR025760NCRR NIH HHS UL1 RR025761NHLBI NIH HHS HL110854NHLBI NIH HHS R01 HL055716NHLBI NIH HHS R01 HL55716NHLBI NIH HHS T35 HL110854NIAMS NIH HHS R01 AR052682NIAMS NIH HHS R01 AR060332NIAMS NIH HHS R01 AR060863NIAMS NIH HHS R03 AR055269NIDDK NIH HHS P30 DK090948NIDDK NIH HHS U54 DK106846
6 · The paper itself

Abstract

Recent studies suggest that megakaryocytes (MKs) may play a significant role in skeletal homeostasis, as evident by the occurrence of osteosclerosis in multiple MK related diseases (Lennert et al., 1975; Thiele et al., 1999; Chagraoui et al., 2006). We previously reported a novel interaction whereby MKs enhanced proliferation of osteoblast lineage/osteoprogenitor cells (OBs) by a mechanism requiring direct cell-cell contact. However, the signal transduction pathways and the downstream effector molecules involved in this process have not been characterized. Here we show that MKs contact with OBs, via beta1 integrin, activate the p38/MAPKAPK2/p90RSK kinase cascade in the bone cells, which causes Mdm2 to neutralizes p53/Rb-mediated check point and allows progression through the G1/S. Interestingly, activation of MAPK (ERK1/2) and AKT, collateral pathways that regulate the cell cycle, remained unchanged with MK stimulation of OBs. The MK-to-OB signaling ultimately results in significant increases in the expression of c-fos and cyclin A, necessary for sustaining the OB proliferation. Overall, our findings show that OBs respond to the presence of MKs, in part, via an integrin-mediated signaling mechanism, activating a novel response axis that de-represses cell cycle activity. Understanding the mechanisms by which MKs enhance OB proliferation will facilitate the development of novel anabolic therapies to treat bone loss associated with osteoporosis and other bone-related diseases.

Indexed as

Cell CycleCell DifferentiationCell LineageCell ProliferationCells, CulturedHumansMAP Kinase Signaling SystemMegakaryocytesOsteoblastsProto-Oncogene Proteins c-mdm2Signal TransductionMDM2 protein, humanProto-Oncogene Proteins c-mdm2

Identifiers

PMID25160801
PMCPMC4433553
OpenAlexW1492796529

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.